Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

723
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
723
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

262
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
262
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

290
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

718
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
718
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

245
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
245
Cytoskeletal Linker Proteins - Plakins01:09

Cytoskeletal Linker Proteins - Plakins

2.5K
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: an analysis from the TREATKids registry.

The Journal of investigative dermatology·2026
Same author

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Allergologie select·2026
Same author

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.

Dermatology and therapy·2026
Same author

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Acta dermato-venereologica·2026
Same author

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

The Journal of dermatological treatment·2026
Same author

Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis.

American journal of clinical dermatology·2026

Related Experiment Video

Updated: Oct 24, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.4K

Tralokinumab in atopic dermatitis.

Andreas Wollenberg1, Stephan Weidinger2, Margitta Worm3

  • 1Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|August 14, 2021
PubMed
Summary

Tralokinumab effectively treats moderate-to-severe atopic dermatitis (AD) by inhibiting interleukin-13 (IL-13). This biologic therapy significantly improved skin lesions and reduced itching in adults, demonstrating a favorable safety profile.

More Related Videos

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.0K

Related Experiment Videos

Last Updated: Oct 24, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.4K
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.0K

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition with significant impact.
  • Pathophysiology involves genetic and environmental factors, leading to barrier dysfunction and immune dysregulation.
  • Interleukin-13 (IL-13) plays a central role in the type-2 immune response characteristic of AD.

Purpose of the Study:

  • To evaluate the efficacy and safety of tralokinumab, an IL-13 inhibitor, in adults with moderate-to-severe atopic dermatitis.
  • Assess tralokinumab's impact on skin clearance, pruritus, and quality of life.

Main Methods:

  • Three pivotal Phase III clinical trials investigated tralokinumab 300 mg every two weeks (Q2W) subcutaneously (SC).
  • Adult patients with moderate-to-severe AD inadequately controlled by topical corticosteroids were included.
  • Primary endpoints included achieving Investigator Global Assessment (IGA) 0/1 and Eczema Area and Severity Index (EASI) 75 at week 16.

Main Results:

  • Tralokinumab demonstrated significant superiority over placebo in achieving IGA 0/1 and EASI-75 at week 16.
  • Secondary endpoints, including reduction in pruritus (worst daily pruritus), DLQI, and SCORAD, were also significantly improved.
  • Treatment effects were sustained during follow-up, and tralokinumab exhibited a safety profile comparable to placebo.

Conclusions:

  • Tralokinumab is an effective and well-tolerated treatment for moderate-to-severe atopic dermatitis in adults.
  • Targeting IL-13 with tralokinumab offers a promising therapeutic option for managing AD.
  • Sustained efficacy and safety support the use of tralokinumab in this patient population.